Identification

Name
Bendroflumethiazide
Accession Number
DB00436  (APRD00666)
Type
Small Molecule
Groups
Approved
Description

A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810)

Structure
Thumb
Synonyms
  • +--3-Benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
  • 6-Trifluoromethyl-3-benzyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide
  • Bendrofluazide
  • Bendroflumethiazid
  • Bendrofluméthiazide
  • Bendroflumethiazidum
  • Bendroflumetiazida
  • Benzhydroflumethiazide
External IDs
BE 724-A / FT 81
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Naturetin 5mgTablet5 mgOralSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1959-12-311999-01-07Canada
International/Other Brands
Aprinox (Sovereign Medical) / Centyl (LEO Pharma) / Naturetin / Neo-Naclex (GlaxoSmithKline) / Salures (Pfizer)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
CorzideBendroflumethiazide (5 mg/1) + Nadolol (80 mg/1)TabletOralPfizer Laboratories Div Pfizer Inc.1983-05-25Not applicableUs
CorzideBendroflumethiazide (5 mg/1) + Nadolol (40 mg/1)TabletOralPfizer Laboratories Div Pfizer Inc.1983-05-25Not applicableUs
Corzide Tab W Nadolol 40mgBendroflumethiazide (5 mg) + Nadolol (40 mg)TabletOralSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1987-12-311997-08-14Canada
Corzide Tab W Nadolol 80mgBendroflumethiazide (5 mg) + Nadolol (80 mg)TabletOralSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1987-12-311997-08-14Canada
Nadolol and BendroflumethiazideBendroflumethiazide (5 mg/1) + Nadolol (40 mg/1)TabletOralImpax Generics2007-03-30Not applicableUs
Nadolol and BendroflumethiazideBendroflumethiazide (5 mg/1) + Nadolol (80 mg/1)TabletOralImpax Generics2007-03-30Not applicableUs
Categories
UNII
5Q52X6ICJI
CAS number
73-48-3
Weight
Average: 421.415
Monoisotopic: 421.037781946
Chemical Formula
C15H14F3N3O4S2
InChI Key
HDWIHXWEUNVBIY-UHFFFAOYSA-N
InChI
InChI=1S/C15H14F3N3O4S2/c16-15(17,18)10-7-11-13(8-12(10)26(19,22)23)27(24,25)21-14(20-11)6-9-4-2-1-3-5-9/h1-5,7-8,14,20-21H,6H2,(H2,19,22,23)
IUPAC Name
3-benzyl-1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1λ⁶,2,4-benzothiadiazine-7-sulfonamide
SMILES
NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F

Pharmacology

Indication

For the treatment of high blood pressure and management of edema related to heart failure.

Structured Indications
Pharmacodynamics

Bendroflumethiazide, a thiazide diuretic, removes excess water from the body by increasing how often you urinate (pass water) and also widens the blood vessels which helps to reduce blood pressure. It inhibits Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.

Mechanism of action

As a diuretic, bendroflumethiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like bendroflumethiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of bendroflumethiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.

TargetActionsOrganism
ASolute carrier family 12 member 3
inhibitor
Human
ACalcium-activated potassium channel subunit alpha-1
inducer
Human
UCarbonic anhydrase 1
inhibitor
Human
UCarbonic anhydrase 2
inhibitor
Human
UCarbonic anhydrase 4
inhibitor
Human
Absorption

Absorbed relatively rapidly after oral administration

Volume of distribution
Not Available
Protein binding

96%

Metabolism
Not Available
Route of elimination
Not Available
Half life

8.5 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Bendroflumethiazide Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Bendroflumethiazide.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Bendroflumethiazide.Experimental, Illicit
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Bendroflumethiazide.Investigational
5-androstenedione5-androstenedione may increase the hypokalemic activities of Bendroflumethiazide.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Bendroflumethiazide.Experimental
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Bendroflumethiazide.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Acebutolol.Approved
AceclofenacThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Aceclofenac.Approved, Investigational
AcemetacinThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Acemetacin.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Bendroflumethiazide.Investigational, Withdrawn
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Acetyldigitoxin.Approved
AcetyldigoxinThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Acetyldigoxin.Experimental
Acetylsalicylic acidThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AclidiniumThe serum concentration of Bendroflumethiazide can be increased when it is combined with Aclidinium.Approved
AdapaleneThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Adapalene.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Bendroflumethiazide.Experimental, Investigational
AlaproclateAlaproclate may increase the hyponatremic activities of Bendroflumethiazide.Experimental
AlclofenacThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlclometasoneAlclometasone may increase the hypokalemic activities of Bendroflumethiazide.Approved
AlcuroniumThe serum concentration of Bendroflumethiazide can be increased when it is combined with Alcuronium.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Bendroflumethiazide.Approved
AldosteroneAldosterone may increase the hypokalemic activities of Bendroflumethiazide.Experimental, Investigational
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Bendroflumethiazide.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Bendroflumethiazide.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Aliskiren.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Bendroflumethiazide.Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Bendroflumethiazide.Approved
AlminoprofenThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Alminoprofen.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Bendroflumethiazide.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Bendroflumethiazide.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Bendroflumethiazide.Illicit
AlprenololBendroflumethiazide may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanBendroflumethiazide may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmcinonideAmcinonide may increase the hypokalemic activities of Bendroflumethiazide.Approved
AmifostineBendroflumethiazide may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Amiloride.Approved
AmiodaroneBendroflumethiazide may increase the bradycardic activities of Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Bendroflumethiazide.Approved
AmobarbitalAmobarbital may increase the orthostatic hypotensive activities of Bendroflumethiazide.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Bendroflumethiazide.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Amyl Nitrite.Approved
AndrographolideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Andrographolide.Investigational
AndrostenedioneAndrostenedione may increase the hypokalemic activities of Bendroflumethiazide.Experimental, Illicit
AnecortaveAnecortave may increase the hypokalemic activities of Bendroflumethiazide.Investigational
anecortave acetateanecortave acetate may increase the hypokalemic activities of Bendroflumethiazide.Investigational
AnisodamineThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Anisodamine.Investigational
Anisotropine MethylbromideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Anisotropine Methylbromide.Approved
AntipyrineThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Antipyrine.Approved
ApocyninThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Apocynin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Bendroflumethiazide.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Apraclonidine.Approved
ApremilastThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Apremilast.Approved, Investigational
ArbutamineArbutamine may increase the hypokalemic activities of Bendroflumethiazide.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Bendroflumethiazide.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Bendroflumethiazide.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Bendroflumethiazide.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Bendroflumethiazide.Approved, Investigational
AtamestaneAtamestane may increase the hypokalemic activities of Bendroflumethiazide.Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Bendroflumethiazide.Approved
AtracuriumThe serum concentration of Bendroflumethiazide can be increased when it is combined with Atracurium.Experimental, Investigational
Atracurium besylateThe serum concentration of Bendroflumethiazide can be increased when it is combined with Atracurium besylate.Approved
AtropineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Atropine.Approved, Vet Approved
AzapropazoneThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Azilsartan medoxomil.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Bendroflumethiazide.Investigational
BalsalazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Balsalazide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Bendroflumethiazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the orthostatic hypotensive activities of Bendroflumethiazide.Experimental
BarbitalBarbital may increase the orthostatic hypotensive activities of Bendroflumethiazide.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Bendroflumethiazide.Approved
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Bendroflumethiazide.Approved, Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Bendroflumethiazide.Investigational
BenactyzineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Benactyzine.Withdrawn
BenazeprilThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Benazepril.Approved, Investigational
BendazacThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Bendazac.Experimental
BenmoxinBenmoxin may increase the hypotensive activities of Bendroflumethiazide.Withdrawn
BenorilateThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzatropineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Benzatropine.Approved
BepridilBendroflumethiazide may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BeractantBendroflumethiazide may increase the bradycardic activities of Beractant.Approved
BetamethasoneBetamethasone may increase the hypokalemic activities of Bendroflumethiazide.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Bendroflumethiazide.Approved
BethanidineBethanidine may increase the hypotensive activities of Bendroflumethiazide.Approved
BevoniumThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Bevonium.Experimental
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Bendroflumethiazide.Experimental, Illicit, Withdrawn
BietaserpineBietaserpine may increase the hypotensive activities of Bendroflumethiazide.Experimental
BimatoprostBendroflumethiazide may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BiperidenThe serum concentration of Bendroflumethiazide can be increased when it is combined with Biperiden.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Bisoprolol.Approved
BornaprineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Bornaprine.Experimental
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Bendroflumethiazide.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Bendroflumethiazide.Approved, Investigational
BQ-123Bendroflumethiazide may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the bradycardic activities of Bendroflumethiazide.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Bendroflumethiazide.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Bendroflumethiazide.Experimental
BromfenacThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Bendroflumethiazide.Approved, Investigational
BucillamineThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Bucillamine.Investigational
BudesonideBudesonide may increase the hypokalemic activities of Bendroflumethiazide.Approved
BufexamacThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Bufexamac.Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Bendroflumethiazide.Investigational, Withdrawn
BumadizoneThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Bendroflumethiazide.Approved, Investigational
BupranololBendroflumethiazide may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Bendroflumethiazide.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Bendroflumethiazide.Approved, Illicit, Vet Approved
CadralazineCadralazine may increase the hypotensive activities of Bendroflumethiazide.Experimental
CafedrineBendroflumethiazide may increase the hypotensive activities of Cafedrine.Investigational
CalcidiolBendroflumethiazide may increase the hypercalcemic activities of Calcidiol.Approved, Nutraceutical
CalcipotriolBendroflumethiazide may increase the hypercalcemic activities of Calcipotriol.Approved
CalciumBendroflumethiazide may decrease the excretion rate of Calcium which could result in a higher serum level.Approved, Nutraceutical
Calcium AcetateBendroflumethiazide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
Calcium CarbonateBendroflumethiazide may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved
Calcium CitrateBendroflumethiazide may decrease the excretion rate of Calcium Citrate which could result in a higher serum level.Approved
Calcium glubionateBendroflumethiazide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved
Calcium GluceptateBendroflumethiazide may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Approved
Calcium gluconateBendroflumethiazide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved, Vet Approved
Calcium lactateBendroflumethiazide may decrease the excretion rate of Calcium lactate which could result in a higher serum level.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateBendroflumethiazide may decrease the excretion rate of Calcium lactate gluconate which could result in a higher serum level.Experimental
Calcium laevulateBendroflumethiazide may decrease the excretion rate of Calcium laevulate which could result in a higher serum level.Experimental
Calcium pangamateBendroflumethiazide may decrease the excretion rate of Calcium pangamate which could result in a higher serum level.Experimental
Calcium PhosphateBendroflumethiazide may decrease the excretion rate of Calcium Phosphate which could result in a higher serum level.Approved
CalfactantBendroflumethiazide may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Candesartan.Approved
CandoxatrilBendroflumethiazide may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Bendroflumethiazide.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Bendroflumethiazide.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Bendroflumethiazide.Illicit, Investigational, Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Bendroflumethiazide.Withdrawn
CarprofenThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Carvedilol.Approved, Investigational
CaseinBendroflumethiazide may decrease the excretion rate of Casein which could result in a higher serum level.Approved
CastanospermineThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Bendroflumethiazide.Approved, Investigational
CeritinibBendroflumethiazide may increase the bradycardic activities of Ceritinib.Approved
ChloroquineThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenoxamineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Chlorphenoxamine.Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Bendroflumethiazide.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Bendroflumethiazide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Bendroflumethiazide.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Bendroflumethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Bendroflumethiazide.Approved, Investigational
CicletanineBendroflumethiazide may increase the hypotensive activities of Cicletanine.Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Bendroflumethiazide.Experimental
CilazaprilThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Bendroflumethiazide.Approved, Investigational
CitalopramCitalopram may increase the hyponatremic activities of Bendroflumethiazide.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Bendroflumethiazide.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Clevidipine.Approved
ClobetasolClobetasol may increase the hypokalemic activities of Bendroflumethiazide.Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Bendroflumethiazide.Approved
ClobetasoneClobetasone may increase the hypokalemic activities of Bendroflumethiazide.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Bendroflumethiazide.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Bendroflumethiazide.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Bendroflumethiazide.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Clonidine.Approved
ClonixinThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Clonixin.Approved
CloranololBendroflumethiazide may increase the hypotensive activities of Cloranolol.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Bendroflumethiazide.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Bendroflumethiazide.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Bendroflumethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Bendroflumethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Bendroflumethiazide.Approved, Investigational
Cortexolone 17α-propionateCortexolone 17α-propionate may increase the hypokalemic activities of Bendroflumethiazide.Investigational
CorticosteroneCorticosterone may increase the hypokalemic activities of Bendroflumethiazide.Experimental
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Bendroflumethiazide.Approved
CrizotinibBendroflumethiazide may increase the bradycardic activities of Crizotinib.Approved
CryptenamineBendroflumethiazide may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Curcumin.Investigational
CyclopenthiazideBendroflumethiazide may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclopentolateThe serum concentration of Bendroflumethiazide can be increased when it is combined with Cyclopentolate.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Cyclophosphamide.Approved, Investigational
CyclothiazideBendroflumethiazide may increase the hypotensive activities of Cyclothiazide.Approved
CymarinThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Cymarin.Experimental
D-LimoneneThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with D-Limonene.Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the hyponatremic activities of Bendroflumethiazide.Investigational
DarifenacinThe serum concentration of Bendroflumethiazide can be increased when it is combined with Darifenacin.Approved, Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Bendroflumethiazide.Approved, Investigational
DelaprilBendroflumethiazide may increase the hypotensive activities of Delapril.Experimental
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Bendroflumethiazide.Investigational
DeserpidineBendroflumethiazide may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Bendroflumethiazide.Approved
DeslanosideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Deslanoside.Approved
DesloratadineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Desloratadine.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Bendroflumethiazide.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Bendroflumethiazide.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Bendroflumethiazide.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the hyponatremic activities of Bendroflumethiazide.Approved
DexamethasoneDexamethasone may increase the hypokalemic activities of Bendroflumethiazide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Bendroflumethiazide.Vet Approved
DexetimideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Dexetimide.Withdrawn
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Bendroflumethiazide.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Bendroflumethiazide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Bendroflumethiazide.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Bendroflumethiazide.Approved, Investigational
DiazoxideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Diazoxide.Approved
DiclofenacThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Diclofenamide.Approved
DicyclomineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Dicyclomine.Approved
diethylnorspermineBendroflumethiazide may increase the hypotensive activities of diethylnorspermine.Investigational
DifenpiramideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Difenpiramide.Experimental
DiflorasoneDiflorasone may increase the hypokalemic activities of Bendroflumethiazide.Approved
DiflunisalThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Diflunisal.Approved
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Bendroflumethiazide.Approved, Investigational
DifluprednateDifluprednate may increase the hypokalemic activities of Bendroflumethiazide.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Digitoxin.Approved, Investigational
DigoxinThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Digoxin.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Bendroflumethiazide.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Bendroflumethiazide.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Bendroflumethiazide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Bendroflumethiazide.Experimental, Illicit
DihydrotachysterolBendroflumethiazide may increase the hypercalcemic activities of Dihydrotachysterol.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Bendroflumethiazide.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Dinutuximab.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Bendroflumethiazide.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Bendroflumethiazide.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Dipyridamole.Approved
DobutamineDobutamine may increase the hypokalemic activities of Bendroflumethiazide.Approved
DofetilideBendroflumethiazide may increase the QTc-prolonging activities of Dofetilide.Approved
DonepezilBendroflumethiazide may increase the bradycardic activities of Donepezil.Approved
DorzolamideBendroflumethiazide may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Doxazosin.Approved
DoxercalciferolBendroflumethiazide may increase the hypercalcemic activities of Doxercalciferol.Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Bendroflumethiazide.Investigational
DronedaroneBendroflumethiazide may increase the bradycardic activities of Dronedarone.Approved
DroxicamThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Droxicam.Approved
DroxidopaDroxidopa may increase the hypokalemic activities of Bendroflumethiazide.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Bendroflumethiazide.Approved
DuloxetineBendroflumethiazide may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Duvelisib.Investigational
E-6201The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with E-6201.Investigational
EfonidipineBendroflumethiazide may increase the hypotensive activities of Efonidipine.Approved
EmeproniumThe serum concentration of Bendroflumethiazide can be increased when it is combined with Emepronium.Experimental
EmpagliflozinThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Enalapril.Approved, Vet Approved
EnalaprilatBendroflumethiazide may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Bendroflumethiazide.Experimental
EpanololBendroflumethiazide may increase the hypotensive activities of Epanolol.Experimental
EphedraEphedra may increase the hypokalemic activities of Bendroflumethiazide.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Bendroflumethiazide.Approved, Vet Approved
EpirizoleThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Epirizole.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Eplerenone.Approved
EpoprostenolBendroflumethiazide may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Eprosartan.Approved
EquileninEquilenin may increase the hypokalemic activities of Bendroflumethiazide.Experimental
EquilinEquilin may increase the hypokalemic activities of Bendroflumethiazide.Approved
ErgocalciferolBendroflumethiazide may increase the hypercalcemic activities of Ergocalciferol.Approved, Nutraceutical
EscitalopramEscitalopram may increase the hyponatremic activities of Bendroflumethiazide.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Bendroflumethiazide.Approved
EstroneEstrone may increase the hypokalemic activities of Bendroflumethiazide.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Bendroflumethiazide.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Etacrynic acid.Approved
EtanautineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Etanautine.Experimental
EtanerceptThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Etanercept.Approved, Investigational
EthanolEthanol may increase the orthostatic hypotensive activities of Bendroflumethiazide.Approved
EthenzamideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Ethenzamide.Experimental
EthopropazineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Ethopropazine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Bendroflumethiazide.Approved, Illicit
EtodolacThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Etofenamate.Approved, Investigational
EtoperidoneEtoperidone may increase the hyponatremic activities of Bendroflumethiazide.Withdrawn
EtoricoxibThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Bendroflumethiazide.Illicit, Vet Approved
EtybenzatropineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Etybenzatropine.Experimental
Evening primrose oilThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Evening primrose oil.Approved, Investigational
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Bendroflumethiazide.Approved, Investigational
exisulindThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with exisulind.Investigational
FelbinacThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Felbinac.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Felodipine.Approved, Investigational
FenbufenThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Fenbufen.Approved
FenoldopamBendroflumethiazide may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Fenoprofen.Approved
FenoterolFenoterol may increase the hypokalemic activities of Bendroflumethiazide.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Bendroflumethiazide.Approved, Illicit, Investigational, Vet Approved
FentiazacThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Fentiazac.Experimental
FeprazoneThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Feprazone.Experimental
Ferulic acidThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Ferulic acid.Experimental
FesoterodineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Fesoterodine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Bendroflumethiazide.Approved, Investigational
FingolimodBendroflumethiazide may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Floctafenine.Approved, Withdrawn
fluasteronefluasterone may increase the hypokalemic activities of Bendroflumethiazide.Investigational
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Bendroflumethiazide.Approved
FlumethasoneFlumethasone may increase the hypokalemic activities of Bendroflumethiazide.Approved, Vet Approved
FlunixinThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Flunoxaprofen.Experimental
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Bendroflumethiazide.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Bendroflumethiazide.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Bendroflumethiazide.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Bendroflumethiazide.Approved
FluoxetineFluoxetine may increase the hyponatremic activities of Bendroflumethiazide.Approved, Vet Approved
FluprednideneFluprednidene may increase the hypokalemic activities of Bendroflumethiazide.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Bendroflumethiazide.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Bendroflumethiazide.Approved
FlurbiprofenThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FluvoxamineFluvoxamine may increase the hyponatremic activities of Bendroflumethiazide.Approved, Investigational
FormestaneFormestane may increase the hypokalemic activities of Bendroflumethiazide.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Bendroflumethiazide.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Fosinopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Bendroflumethiazide.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Furosemide.Approved, Vet Approved
GalantamineBendroflumethiazide may increase the bradycardic activities of Galantamine.Approved
GallamineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Gallamine.Experimental
Gallamine TriethiodideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Gallamine Triethiodide.Approved
GitoformateThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Gitoformate.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Bendroflumethiazide.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Bendroflumethiazide.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Bendroflumethiazide.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Bendroflumethiazide.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Bendroflumethiazide.Approved, Investigational
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Bendroflumethiazide.Approved
GlycopyrroniumThe serum concentration of Bendroflumethiazide can be increased when it is combined with Glycopyrronium.Approved, Investigational, Vet Approved
GuacetisalThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Guacetisal.Experimental
GuanabenzBendroflumethiazide may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Bendroflumethiazide.Approved
GuanazodineBendroflumethiazide may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Bendroflumethiazide.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Guanfacine.Approved, Investigational
GuanoclorBendroflumethiazide may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzBendroflumethiazide may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanBendroflumethiazide may increase the hypotensive activities of Guanoxan.Experimental
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Bendroflumethiazide.Investigational
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Bendroflumethiazide.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Bendroflumethiazide.Experimental
HE3286HE3286 may increase the hypokalemic activities of Bendroflumethiazide.Investigational
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Bendroflumethiazide.Approved, Illicit, Investigational
HexamethoniumThe serum concentration of Bendroflumethiazide can be increased when it is combined with Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the orthostatic hypotensive activities of Bendroflumethiazide.Approved
HigenamineThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Higenamine.Investigational
HomatropineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Homatropine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Bendroflumethiazide.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Bendroflumethiazide.Approved, Illicit
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Bendroflumethiazide.Approved, Vet Approved
HydroflumethiazideBendroflumethiazide may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Bendroflumethiazide.Approved, Illicit
HyoscyamineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Hyoscyamine.Approved
IbuprofenThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Icatibant.Approved
IloprostIloprost may increase the hypotensive activities of Bendroflumethiazide.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Bendroflumethiazide.Investigational
Imidazole salicylateThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Imidazole salicylate.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Bendroflumethiazide.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Bendroflumethiazide.Approved
IndalpineIndalpine may increase the hyponatremic activities of Bendroflumethiazide.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Indapamide.Approved
IndenololBendroflumethiazide may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Bendroflumethiazide.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Bendroflumethiazide.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Bendroflumethiazide.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Bendroflumethiazide.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Bendroflumethiazide.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Bendroflumethiazide.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Bendroflumethiazide.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Bendroflumethiazide.Approved
Ipratropium bromideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Ipratropium bromide.Approved
IproclozideIproclozide may increase the hypotensive activities of Bendroflumethiazide.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Bendroflumethiazide.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Bendroflumethiazide.Approved
IsoetarineIsoetarine may increase the hypokalemic activities of Bendroflumethiazide.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Bendroflumethiazide.Approved, Vet Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Bendroflumethiazide.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Isosorbide Mononitrate.Approved
IsoxicamThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Bendroflumethiazide.Approved
IstaroximeIstaroxime may increase the hypokalemic activities of Bendroflumethiazide.Investigational
IvabradineBendroflumethiazide may increase the arrhythmogenic activities of Ivabradine.Approved
KebuzoneThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Bendroflumethiazide.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Bendroflumethiazide.Approved, Investigational
KetoprofenThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Labetalol.Approved
LacidipineBendroflumethiazide may increase the hypotensive activities of Lacidipine.Approved, Investigational
LacosamideBendroflumethiazide may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
Lanatoside CThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Lanatoside C.Experimental
LanreotideBendroflumethiazide may increase the bradycardic activities of Lanreotide.Approved
LatanoprostBendroflumethiazide may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Leflunomide.Approved, Investigational
LercanidipineBendroflumethiazide may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Bendroflumethiazide.Approved, Investigational
LevodopaBendroflumethiazide may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Bendroflumethiazide.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the hyponatremic activities of Bendroflumethiazide.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Bendroflumethiazide.Approved
LevosalbutamolLevosalbutamol may increase the hypokalemic activities of Bendroflumethiazide.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Bendroflumethiazide.Approved, Investigational
LicoriceLicorice may increase the hypokalemic activities of Bendroflumethiazide.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Bendroflumethiazide.Approved
LinsidomineBendroflumethiazide may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Bendroflumethiazide.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Lisinopril.Approved, Investigational
LisofyllineThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Lisofylline.Investigational
LithiumBendroflumethiazide may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Bendroflumethiazide.Illicit
LofexidineBendroflumethiazide may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Lonazolac.Experimental
LornoxicamThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Losartan.Approved
LoxoprofenThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Loxoprofen.Approved, Investigational
LucinactantBendroflumethiazide may increase the bradycardic activities of Lucinactant.Approved, Investigational
LumiracoxibThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Lumiracoxib.Approved, Investigational
MacitentanBendroflumethiazide may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Magnesium salicylate.Approved
ManidipineBendroflumethiazide may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Mannitol.Approved, Investigational
MasoprocolThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Masoprocol.Approved, Investigational
MazaticolThe serum concentration of Bendroflumethiazide can be increased when it is combined with Mazaticol.Experimental
ME-609ME-609 may increase the hypokalemic activities of Bendroflumethiazide.Investigational
MebanazineMebanazine may increase the hypotensive activities of Bendroflumethiazide.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Mecamylamine.Approved
Meclofenamic acidThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Bendroflumethiazide.Approved
Mefenamic acidThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Mefenamic acid.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Bendroflumethiazide.Vet Approved
MeloxicamThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Bendroflumethiazide.Experimental
MesalazineThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Metamizole.Investigational, Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Bendroflumethiazide.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Bendroflumethiazide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Bendroflumethiazide.Approved, Illicit
MethanthelineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Methantheline.Approved, Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the orthostatic hypotensive activities of Bendroflumethiazide.Approved
MethoserpidineBendroflumethiazide may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bendroflumethiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Bendroflumethiazide.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Bendroflumethiazide.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the orthostatic hypotensive activities of Bendroflumethiazide.Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Bendroflumethiazide.Approved, Vet Approved
MetildigoxinThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Metildigoxin.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Metipranolol.Approved
MetixeneThe serum concentration of Bendroflumethiazide can be increased when it is combined with Metixene.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Bendroflumethiazide.Approved, Investigational
MetyrosineBendroflumethiazide may increase the hypotensive activities of Metyrosine.Approved
MibefradilBendroflumethiazide may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Bendroflumethiazide.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Bendroflumethiazide.Approved
MilnacipranMilnacipran may increase the hyponatremic activities of Bendroflumethiazide.Approved
MinaprineMinaprine may increase the hypotensive activities of Bendroflumethiazide.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Bendroflumethiazide.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Bendroflumethiazide.Investigational
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Bendroflumethiazide.Approved, Investigational
MizoribineThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Bendroflumethiazide.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Moexipril.Approved
MofebutazoneThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Bendroflumethiazide.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Bendroflumethiazide.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Bendroflumethiazide.Approved, Investigational
MuzolimineBendroflumethiazide may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Bendroflumethiazide.Approved, Investigational
NabumetoneThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Nadolol.Approved
NafamostatThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Nafamostat.Approved, Investigational
NaftifineThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Naftifine.Approved
NaftopidilBendroflumethiazide may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Bendroflumethiazide.Approved
NaproxenThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Naproxen.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Bendroflumethiazide.Approved, Investigational
NCX 1022NCX 1022 may increase the hypokalemic activities of Bendroflumethiazide.Investigational
NebivololThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the hyponatremic activities of Bendroflumethiazide.Approved, Withdrawn
NepafenacThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Bendroflumethiazide.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Nicardipine.Approved
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Bendroflumethiazide.Experimental
NicorandilNicorandil may increase the hypotensive activities of Bendroflumethiazide.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Nifedipine.Approved
NifenazoneThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Niflumic Acid.Approved
NiguldipineBendroflumethiazide may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineBendroflumethiazide may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Bendroflumethiazide.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Bendroflumethiazide.Approved
NitrendipineBendroflumethiazide may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Bendroflumethiazide.Approved
NitroaspirinThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Bendroflumethiazide.Approved
NorepinephrineNorepinephrine may increase the hypokalemic activities of Bendroflumethiazide.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Bendroflumethiazide.Approved, Illicit
ObinutuzumabBendroflumethiazide may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Bendroflumethiazide.Withdrawn
OctreotideOctreotide may increase the bradycardic activities of Bendroflumethiazide.Approved, Investigational
OleandrinThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Oleandrin.Experimental, Investigational
Oleoyl-estroneOleoyl-estrone may increase the hypokalemic activities of Bendroflumethiazide.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bendroflumethiazide.Approved, Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Bendroflumethiazide.Approved
OlopatadineThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Olsalazine.Approved
OmapatrilatBendroflumethiazide may increase the hypotensive activities of Omapatrilat.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Bendroflumethiazide.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Bendroflumethiazide.Approved
OrgoteinThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Orgotein.Vet Approved
OrphenadrineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Orphenadrine.Approved
OtiloniumThe serum concentration of Bendroflumethiazide can be increased when it is combined with Otilonium.Experimental, Investigational
OuabainThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Ouabain.Approved
OxaprozinThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Oxaprozin.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Oxcarbazepine.Approved
OxitropiumThe serum concentration of Bendroflumethiazide can be increased when it is combined with Oxitropium.Investigational
OxprenololBendroflumethiazide may increase the hypotensive activities of Oxprenolol.Approved
OxybutyninThe serum concentration of Bendroflumethiazide can be increased when it is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Bendroflumethiazide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Bendroflumethiazide.Approved, Investigational, Vet Approved
OxyphenbutazoneThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Oxyphenbutazone.Approved, Withdrawn
OxyphenoniumThe serum concentration of Bendroflumethiazide can be increased when it is combined with Oxyphenonium.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Bendroflumethiazide.Approved, Vet Approved
PancuroniumThe serum concentration of Bendroflumethiazide can be increased when it is combined with Pancuronium.Approved
PapaverineThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Papaverine.Approved
ParamethasoneParamethasone may increase the hypokalemic activities of Bendroflumethiazide.Approved
ParecoxibThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Bendroflumethiazide.Approved
ParicalcitolBendroflumethiazide may increase the hypercalcemic activities of Paricalcitol.Approved, Investigational
ParoxetineParoxetine may increase the hyponatremic activities of Bendroflumethiazide.Approved, Investigational
ParthenolideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Parthenolide.Investigational
PasireotideBendroflumethiazide may increase the bradycardic activities of Pasireotide.Approved
PenbutololThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Bendroflumethiazide.Approved, Vet Approved
PentobarbitalPentobarbital may increase the orthostatic hypotensive activities of Bendroflumethiazide.Approved, Vet Approved
PentoliniumThe serum concentration of Bendroflumethiazide can be increased when it is combined with Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Bendroflumethiazide.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Perindopril.Approved
PeruvosideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Bendroflumethiazide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Bendroflumethiazide.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Bendroflumethiazide.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Bendroflumethiazide.Approved, Investigational, Withdrawn
PhenglutarimideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Phenglutarimide.Experimental
PheniprazinePheniprazine may increase the hypotensive activities of Bendroflumethiazide.Withdrawn
PhenobarbitalPhenobarbital may increase the orthostatic hypotensive activities of Bendroflumethiazide.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Bendroflumethiazide.Experimental
PhenoxybenzamineBendroflumethiazide may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Bendroflumethiazide.Withdrawn
PhentolamineBendroflumethiazide may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Bendroflumethiazide.Approved, Vet Approved, Withdrawn
PimecrolimusThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Bendroflumethiazide.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Pindolol.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Bendroflumethiazide.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Bendroflumethiazide.Approved, Investigational
PipecuroniumThe serum concentration of Bendroflumethiazide can be increased when it is combined with Pipecuronium.Approved
PirbuterolPirbuterol may increase the hypokalemic activities of Bendroflumethiazide.Approved
PirenzepineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Pirenzepine.Approved
PirfenidoneThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Pirfenidone.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Bendroflumethiazide.Investigational
PirlindolePirlindole may increase the hypotensive activities of Bendroflumethiazide.Approved
PiroxicamThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Pirprofen.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Bendroflumethiazide.Withdrawn
PolythiazideBendroflumethiazide may increase the hypotensive activities of Polythiazide.Approved
Poractant alfaBendroflumethiazide may increase the bradycardic activities of Poractant alfa.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Bendroflumethiazide.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Bendroflumethiazide.Approved, Investigational
PranoprofenThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Pranoprofen.Experimental, Investigational
PrasteronePrasterone may increase the hypokalemic activities of Bendroflumethiazide.Approved, Nutraceutical
Prasterone sulfatePrasterone sulfate may increase the hypokalemic activities of Bendroflumethiazide.Investigational
PrazosinThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Prazosin.Approved
PrednicarbatePrednicarbate may increase the hypokalemic activities of Bendroflumethiazide.Approved
PrednisolonePrednisolone may increase the hypokalemic activities of Bendroflumethiazide.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Bendroflumethiazide.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Bendroflumethiazide.Experimental, Investigational
PrimidonePrimidone may increase the orthostatic hypotensive activities of Bendroflumethiazide.Approved, Vet Approved
ProcaterolProcaterol may increase the hypokalemic activities of Bendroflumethiazide.Approved, Investigational
ProcyclidineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Procyclidine.Approved
ProglumetacinThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Proglumetacin.Experimental
PropacetamolThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Propacetamol.Approved, Investigational
PropafenoneBendroflumethiazide may increase the bradycardic activities of Propafenone.Approved
PropanthelineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Propantheline.Approved
PropiverineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Propiverine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Bendroflumethiazide.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Propranolol.Approved, Investigational
PropyphenazoneThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Proquazone.Experimental
ProscillaridinThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Proscillaridin.Experimental
PTC299The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Bendroflumethiazide.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Bendroflumethiazide.Approved
RasagilineRasagiline may increase the hypotensive activities of Bendroflumethiazide.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Bendroflumethiazide.Approved
RemikirenRemikiren may increase the hypotensive activities of Bendroflumethiazide.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Bendroflumethiazide.Approved, Investigational
RescinnamineBendroflumethiazide may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Bendroflumethiazide.Approved, Investigational
ResveratrolThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Resveratrol.Approved, Experimental, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Bendroflumethiazide.Investigational
RimexoloneRimexolone may increase the hypokalemic activities of Bendroflumethiazide.Approved
RiociguatThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Riociguat.Approved
RisperidoneBendroflumethiazide may increase the hypotensive activities of Risperidone.Approved, Investigational
RitodrineRitodrine may increase the hypokalemic activities of Bendroflumethiazide.Approved, Investigational
RituximabBendroflumethiazide may increase the hypotensive activities of Rituximab.Approved
RivastigmineBendroflumethiazide may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RofecoxibThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Bendroflumethiazide.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Bendroflumethiazide.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Bendroflumethiazide.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Bendroflumethiazide.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Bendroflumethiazide.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Bendroflumethiazide.Approved
SafrazineSafrazine may increase the hypotensive activities of Bendroflumethiazide.Withdrawn
SalbutamolSalbutamol may increase the hypokalemic activities of Bendroflumethiazide.Approved, Vet Approved
SalicylamideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Bendroflumethiazide.Approved
SalsalateThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Salsalate.Approved
SaprisartanBendroflumethiazide may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Bendroflumethiazide.Approved
ScopolamineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Scopolamine.Approved
Scopolamine butylbromideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Scopolamine butylbromide.Approved, Vet Approved
SecobarbitalSecobarbital may increase the orthostatic hypotensive activities of Bendroflumethiazide.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Bendroflumethiazide.Approved, Investigational, Vet Approved
SelexipagBendroflumethiazide may increase the hypotensive activities of Selexipag.Approved
SemapimodThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Semapimod.Investigational
SeratrodastThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Seratrodast.Approved
SerrapeptaseThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Serrapeptase.Investigational
SertralineSertraline may increase the hyponatremic activities of Bendroflumethiazide.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Bendroflumethiazide.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Bendroflumethiazide.Approved, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Bendroflumethiazide.Approved, Investigational
SitaxentanBendroflumethiazide may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Bendroflumethiazide.Approved
Sodium phosphateBendroflumethiazide may increase the nephrotoxic activities of Sodium phosphate.Approved
SolifenacinThe serum concentration of Bendroflumethiazide can be increased when it is combined with Solifenacin.Approved
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Bendroflumethiazide.Investigational
SotalolThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Sotalol.Approved
SpiraprilBendroflumethiazide may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Bendroflumethiazide.Approved
SRT501The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Bendroflumethiazide.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Bendroflumethiazide.Approved, Investigational
SulfasalazineThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Sulindac.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Bendroflumethiazide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Sulpiride.Approved, Investigational
SuprofenThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Suxibuzone.Experimental
TadalafilTadalafil may increase the antihypertensive activities of Bendroflumethiazide.Approved, Investigational
TalinololBendroflumethiazide may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Bendroflumethiazide.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Bendroflumethiazide.Approved
TarenflurbilThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tarenflurbil.Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Telmisartan.Approved, Investigational
TemocaprilBendroflumethiazide may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tenidap.Experimental
TenoxicamThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Terazosin.Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Bendroflumethiazide.Approved
TeriflunomideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Teriflunomide.Approved
TerlipressinBendroflumethiazide may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineBendroflumethiazide may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Bendroflumethiazide.Approved, Investigational, Withdrawn
TheodrenalineBendroflumethiazide may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThiamylal may increase the orthostatic hypotensive activities of Bendroflumethiazide.Approved, Vet Approved
ThiopentalThiopental may increase the orthostatic hypotensive activities of Bendroflumethiazide.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Bendroflumethiazide.Approved, Withdrawn
Tiaprofenic acidThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tiaprofenic acid.Approved
TiboloneBendroflumethiazide may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenBendroflumethiazide may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Bendroflumethiazide.Experimental
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Bendroflumethiazide.Approved
TinoridineThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tinoridine.Investigational
TiotropiumThe serum concentration of Bendroflumethiazide can be increased when it is combined with Tiotropium.Approved
TixocortolTixocortol may increase the hypokalemic activities of Bendroflumethiazide.Approved
TizanidineThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Tizanidine.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Bendroflumethiazide.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Bendroflumethiazide.Approved
TolazolineBendroflumethiazide may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Bendroflumethiazide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Bendroflumethiazide.Approved, Withdrawn
Tolfenamic AcidThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tolfenamic Acid.Approved
TolmetinThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tolmetin.Approved
TolonidineBendroflumethiazide may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Bendroflumethiazide.Approved
TolterodineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Tolterodine.Approved, Investigational
TopiramateBendroflumethiazide may increase the hypokalemic activities of Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Bendroflumethiazide.Approved
ToremifeneBendroflumethiazide may increase the hypercalcemic activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Bendroflumethiazide.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Trandolapril.Approved
TranilastThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bendroflumethiazide.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Bendroflumethiazide.Approved
TravoprostTravoprost may increase the hypotensive activities of Bendroflumethiazide.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Bendroflumethiazide.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Bendroflumethiazide.Approved, Investigational, Nutraceutical
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Bendroflumethiazide.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Bendroflumethiazide.Approved
TribenosideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tribenoside.Experimental
TrichlormethiazideBendroflumethiazide may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrihexyphenidylThe serum concentration of Bendroflumethiazide can be increased when it is combined with Trihexyphenidyl.Approved
TrimazosinTrimazosin may increase the hypotensive activities of Bendroflumethiazide.Experimental
TrimethaphanThe serum concentration of Bendroflumethiazide can be increased when it is combined with Trimethaphan.Approved, Investigational
TriptolideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Triptolide.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Bendroflumethiazide.Investigational, Withdrawn
TropatepineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Tropatepine.Experimental
TropicamideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Tropicamide.Approved
TrospiumThe serum concentration of Bendroflumethiazide can be increased when it is combined with Trospium.Approved
TubocurarineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Tubocurarine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Bendroflumethiazide.Approved, Investigational
UnoprostoneBendroflumethiazide may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may increase the hypotensive activities of Bendroflumethiazide.Investigational
ValdecoxibThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Valdecoxib.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Bendroflumethiazide.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Bendroflumethiazide.Approved
VecuroniumThe serum concentration of Bendroflumethiazide can be increased when it is combined with Vecuronium.Approved
VenlafaxineVenlafaxine may increase the hyponatremic activities of Bendroflumethiazide.Approved
VerapamilThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Verapamil.Approved
VilanterolVilanterol may increase the hypokalemic activities of Bendroflumethiazide.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Bendroflumethiazide.Approved, Investigational
VincamineBendroflumethiazide may increase the hypotensive activities of Vincamine.Experimental
VinpocetineBendroflumethiazide may increase the hypotensive activities of Vinpocetine.Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Bendroflumethiazide.Approved, Investigational
XipamideBendroflumethiazide may increase the hypotensive activities of Xipamide.Experimental
XylometazolineBendroflumethiazide may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Bendroflumethiazide.Approved, Vet Approved
ZaltoprofenThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Zaltoprofen.Approved, Investigational
ZileutonThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the hyponatremic activities of Bendroflumethiazide.Withdrawn
ZofenoprilBendroflumethiazide may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Zomepirac.Withdrawn
Food Interactions
  • Take with food to increase bioavailability.

References

Synthesis Reference

Goldberg, M.; U.S. Patent 3,265,573; August 9, 1966; assigned to E.R. Squibb & Sons, Inc. Lund, F., Lyngby, K. and Godtfredsen, W.O.; U.S. Patent 3,392,168; July 9, 1968; assigned to Lovens Kemiske Fabrik ved A. Kongsted, Denmark.

General References
Not Available
External Links
Human Metabolome Database
HMDB14580
KEGG Drug
D00650
KEGG Compound
C07758
PubChem Compound
2315
PubChem Substance
46508672
ChemSpider
2225
ChEBI
3013
ChEMBL
CHEMBL1684
Therapeutic Targets Database
DAP000188
PharmGKB
PA448563
Drugs.com
Drugs.com Drug Page
Wikipedia
Bendroflumethiazide
ATC Codes
C03EA13 — Bendroflumethiazide and potassium-sparing agentsC03AA01 — BendroflumethiazideC03AB01 — Bendroflumethiazide and potassiumG01AE10 — Combinations of sulfonamides
MSDS
Download (72.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers2
4CompletedTreatmentHypertensive1

Pharmacoeconomics

Manufacturers
  • Apothecon inc div bristol myers squibb
Packagers
Dosage forms
FormRouteStrength
TabletOral
TabletOral5 mg
Prices
Unit descriptionCostUnit
Bendroflumethiazide powder45.0USD g
Corzide 80-5 tablet4.29USD tablet
Corzide 40-5 mg tablet3.46USD tablet
Corzide 40-5 tablet3.35USD tablet
Corzide 80-5 mg tablet3.23USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)222-223 °CGoldberg, M.; U.S. Patent 3,265,573; August 9, 1966; assigned to E.R. Squibb & Sons, Inc. Lund, F., Lyngby, K. and Godtfredsen, W.O.; U.S. Patent 3,392,168; July 9, 1968; assigned to Lovens Kemiske Fabrik ved A. Kongsted, Denmark.
water solubility108 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.89BERTHOD,A ET AL. (1999)
logS-3.59ADME Research, USCD
pKa8.5SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.214 mg/mLALOGPS
logP1.83ALOGPS
logP1.7ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)9.04ChemAxon
pKa (Strongest Basic)-3.1ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area118.36 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity93.68 m3·mol-1ChemAxon
Polarizability36.92 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9643
Blood Brain Barrier-0.7807
Caco-2 permeable-0.7105
P-glycoprotein substrateNon-substrate0.6048
P-glycoprotein inhibitor INon-inhibitor0.7889
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.8835
CYP450 2C9 substrateNon-substrate0.708
CYP450 2D6 substrateNon-substrate0.8398
CYP450 3A4 substrateNon-substrate0.6596
CYP450 1A2 substrateInhibitor0.8745
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9351
CYP450 2C19 inhibitorNon-inhibitor0.9287
CYP450 3A4 inhibitorNon-inhibitor0.8607
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9081
Ames testNon AMES toxic0.8474
CarcinogenicityNon-carcinogens0.8156
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.0888 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9858
hERG inhibition (predictor II)Non-inhibitor0.8967
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00di-0353900000-1c8856fba9af1de07f87
MS/MS Spectrum - , positiveLC-MS/MSsplash10-044i-3891000000-67bb3f0457a6200bf63e

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1,2,4-benzothiadiazine-1,1-dioxides. These are aromatic heterocyclic compounds containing a 1,2,4-benzothiadiazine ring system with two S=O bonds at the 1-position.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Thiadiazines
Sub Class
Benzothiadiazines
Direct Parent
1,2,4-benzothiadiazine-1,1-dioxides
Alternative Parents
Secondary alkylarylamines / Organosulfonamides / Benzene and substituted derivatives / Aminosulfonyl compounds / Azacyclic compounds / Organopnictogen compounds / Organofluorides / Organic oxides / Hydrocarbon derivatives / Alkyl fluorides
Substituents
1,2,4-benzothiadiazine-1,1-dioxide / Secondary aliphatic/aromatic amine / Monocyclic benzene moiety / Benzenoid / Organosulfonic acid amide / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Aminosulfonyl compound / Sulfonyl / Secondary amine
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
sulfonamide, benzothiadiazine (CHEBI:3013)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Key mediator of sodium and chloride reabsorption in this nephron segment, accounting for a significant fraction of renal sodium reabsorption.
Gene Name
SLC12A3
Uniprot ID
P55017
Uniprot Name
Solute carrier family 12 member 3
Molecular Weight
113138.04 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Monroy A, Plata C, Hebert SC, Gamba G: Characterization of the thiazide-sensitive Na(+)-Cl(-) cotransporter: a new model for ions and diuretics interaction. Am J Physiol Renal Physiol. 2000 Jul;279(1):F161-9. [PubMed:10894798]
  3. Vallon V, Rieg T, Ahn SY, Wu W, Eraly SA, Nigam SK: Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics. Am J Physiol Renal Physiol. 2008 Apr;294(4):F867-73. doi: 10.1152/ajprenal.00528.2007. Epub 2008 Jan 23. [PubMed:18216144]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inducer
General Function
Voltage-gated potassium channel activity
Specific Function
Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+). It is also activated by the concentration of cytosolic Mg(2+). Its activati...
Gene Name
KCNMA1
Uniprot ID
Q12791
Uniprot Name
Calcium-activated potassium channel subunit alpha-1
Molecular Weight
137558.115 Da
References
  1. Tricarico D, Barbieri M, Mele A, Carbonara G, Camerino DC: Carbonic anhydrase inhibitors are specific openers of skeletal muscle BK channel of K+-deficient rats. FASEB J. 2004 Apr;18(6):760-1. Epub 2004 Feb 6. [PubMed:14766795]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name
CA1
Uniprot ID
P00915
Uniprot Name
Carbonic anhydrase 1
Molecular Weight
28870.0 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion in...
Gene Name
CA2
Uniprot ID
P00918
Uniprot Name
Carbonic anhydrase 2
Molecular Weight
29245.895 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina an...
Gene Name
CA4
Uniprot ID
P22748
Uniprot Name
Carbonic anhydrase 4
Molecular Weight
35032.075 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Thiopurine s-methyltransferase activity
Specific Function
Catalyzes the S-methylation of thiopurine drugs such as 6-mercaptopurine.
Gene Name
TPMT
Uniprot ID
P51580
Uniprot Name
Thiopurine S-methyltransferase
Molecular Weight
28180.09 Da
References
  1. Lysaa RA, Giverhaug T, Wold HL, Aarbakke J: Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide. Eur J Clin Pharmacol. 1996;49(5):393-6. [PubMed:8866635]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:37